The Library
Treatment & Research reports
121 reports, newest first · page 1 of 5
2026
- Oral Alintegimod (7HP349) Trial Adds Mesothelioma to Its Cohorts
- Italian Imaging-Meso Study Maps the Mesothelioma Immune Map
- MDNA11 IL-2 Superkine Trial Includes Pleural Mesothelioma
- Rina-S Trial Adds Mesothelioma to Its Tumor Cohorts
- TNG462 Trial: PRMT5 Inhibitor for MTAP-Deleted Mesothelioma
- STEALTH-001 Trial Tests VET3-TGI Oncolytic Virus in Solid Tumors
- VT3989 TEAD Inhibitor Trial Opens to Mesothelioma Patients
- NCI Registry Tracks 1,000 Mesothelioma Patients and Families With BAP1 Mutations (NCT03830229)
- Former South African Asbestos Miners Face Higher Mortality, UCT Study Finds
- 3D Mesothelioma Spheroids Reveal Why Chemo Often Fails
- Mesothelioma Prognosis: ECOG Score Spans 4 to 14 Months
- HIPEC and Cytoreductive Surgery for Peritoneal Mesothelioma: Who Qualifies and What to Expect
- How to Find and Join a Mesothelioma Trial
- First-Line Mesothelioma Treatment: 18.1 vs. 14.1 Months
- Second-Line Mesothelioma Treatment: When First-Line Stops Working, What Comes Next
- Mesothelioma Survival Rates by Stage and Histology: What the Trial Data Actually Show
- Pleurectomy/Decortication vs Extrapleural Pneumonectomy: How Mesothelioma Surgery Decisions Are Made
- Stage 1 Pleural Mesothelioma: Operable Disease and the Multimodal Treatment Window
- Stage 2 Pleural Mesothelioma: Borderline-Operable Disease and the Induction-Therapy Decision
- Stage 3 Pleural Mesothelioma: Inoperable Disease, Immunotherapy, and the Active Trial Landscape
- Mesothelioma Chest Pain: How It Differs from Cardiac, Pleural, and Muscular Causes
- Mesothelioma Early Warning Signs: What to Notice 20 to 50 Years After Asbestos Exposure
- The Mesothelioma Symptom Timeline: From Latency to Late-Stage Progression
- Pleural Effusion in Mesothelioma: Drainage, Recurrence, and What It Means for Prognosis
- Stage 4 Mesothelioma: What to Expect and How Late-Stage Symptoms Are Managed
- Two Chemo-Combo Trials, Two Very Different Signals
- FDA Grants Orphan Drug Status to Orion's ODM-212
- V Foundation Awards $1 Million Grant to UH Cancer Center for BAP1 Mesothelioma Research
- Louisiana Mesothelioma by the Numbers: Avondale, Refineries, and a One Year Deadline
- New Jersey Mesothelioma by the Numbers: Shipyards, Refineries, and a Century of Exposure